Disease

Nasopharyngeal Carcinoma

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · PHASE 1 TRIAL

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

ClinicalTrials.gov

Phase 1 dose-escalation and expansion trial of a novel targeted radiopharmaceutical in multiple somatostatin-receptor–positive cancers; no results reported in this registry record.

Preliminary[212Pb]VMT-alpha-NET Esthesioneuroblastoma Nasopharyngeal Carcinoma

Reported

Planned enrollment120

Study phasePhase 1

Primary outcome: MTD and safetyDLTs through 12 weeks (dose escalation); al…

AUG 17, 2026 · JOURNAL ARTICLE

The current role of immunotherapy in treating nasopharyngeal carcinoma.

Human Vaccines & Immunotherapeutics

This is a comprehensive narrative review synthesizing evidence on immunotherapy's current role in nasopharyngeal carcinoma management, drawing on completed and ongoing clinical trials to inform clinical practice and research priorities.

Expert GuidanceNasopharyngeal Carcinoma Immune Checkpoint Inhibitors Nasopharyngeal Neoplasms

Study details

DesignNarrative review

InterventionProgrammed death-1/programmed death ligand-…